SCHEMBL23668187

SCHEMBL23668187

CC1(C)OB(c2cn(S(=O)(=O)Cc3ccccc3)c3c(Cl)nccc23)OC1(C)C

nearest known ligand 0.34

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ DGAT1 O75907 1/20 0.34
▸ PDE4A P27815 1/20 0.33
▸ PDE4B Q07343 1/20 0.33
▸ PDE4C Q08493 1/20 0.33
▸ PDE4D Q08499 1/20 0.33
▸ CYP2C19 P33261 1/20 0.32
▸ LMNA P02545 1/20 0.32
▸ KMT2A Q03164 1/20 0.32
▸ ANPEP P15144 1/20 0.31
▸ LAP3 P28838 1/20 0.31
▸ GRM4 Q14833 1/20 0.31
▸ KDM4E B2RXH2 1/20 0.31
▸ ALDH1A1 P00352 1/20 0.31
▸ HPGD P15428 1/20 0.31
▸ HSD11B1 P28845 1/20 0.30
▸ KLKB1 P03952 1/20 0.30
▸ DYRK1A Q13627 1/20 0.30
▸ CDK2 P24941 1/20 0.30
▸ DYRK1B Q9Y463 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23668185 0.80 PIK3C3 (0.33) ALDH1A1
SCHEMBL28604695 0.80 ANPEP (0.35) PDE4APDE4BPDE4CPDE4DCYP2C19
SCHEMBL28333074 0.80 ALDH1A1 (0.38) DGAT1PDE4APDE4BPDE4CPDE4D
SCHEMBL28852707 0.79 HTR6 (0.36) CYP2C19ANPEPLAP3ALDH1A1HPGD
SCHEMBL29414040 0.79 HTR6 (0.36) CYP2C19ANPEPLAP3ALDH1A1HPGD
SCHEMBL21870788 0.78 L3MBTL1 (0.35) CYP2C19KMT2AGRM4KDM4EALDH1A1
SCHEMBL28606806 0.76 NPC1 (0.39) CYP2C19LMNAKMT2AALDH1A1HPGD
SCHEMBL28473998 0.76 MAPT (0.36) DGAT1CYP2C19ANPEPLAP3HPGD
SCHEMBL28333115 0.76 DGAT1 (0.33) DGAT1PDE4APDE4BPDE4CPDE4D
SCHEMBL23403834 0.75 PDE4A (0.35) DGAT1PDE4APDE4BPDE4CPDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12234232-B2 Aromatic heterocyclic compound with kinase inhibitory activity SHANGHAI ENNOVABIO PHARMACEUTICALS CO., LTD. (CN) 2025-02-25 — — US disclosed
US-20210371415-A1 AROMATIC HETEROCYCLIC COMPOUND WITH KINASE INHIBITORY ACTIVITY SHANGHAI ENNOVABIO PHARMACEUTICALS CO., LTD. (CN) 2021-12-02 — — US disclosed
EP-3854793-A1 AROMATIC HETEROCYCLIC COMPOUND WITH KINASE INHIBITORY ACTIVITY Shanghai Ennovabio Pharmaceuticals Co., Ltd. (CN) 2021-07-28 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210371415-A1 AROMATIC HETEROCYCLIC COMPOUND WITH KINASE INHIBITORY ACTIVITY JAK1, JAK2, JAK3 DGAT1 3961/4885PDE4A 2654/4885PDE4B 2185/4885
US-12234232-B2 Aromatic heterocyclic compound with kinase inhibitory activity JAK1, JAK2, JAK3 DGAT1 3961/4885PDE4A 2654/4885PDE4B 2185/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback